Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,132,280 shares of the biopharmaceutical company’s stock after purchasing an additional 115,594 shares during the period. AustralianSuper Pty Ltd’s holdings in Gilead Sciences were worth $94,930,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Allspring Global Investments Holdings LLC boosted its stake in Gilead Sciences by 3.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 922,960 shares of the biopharmaceutical company’s stock valued at $67,607,000 after purchasing an additional 35,021 shares in the last quarter. Maryland State Retirement & Pension System raised its holdings in shares of Gilead Sciences by 0.9% in the 1st quarter. Maryland State Retirement & Pension System now owns 98,139 shares of the biopharmaceutical company’s stock worth $6,599,000 after purchasing an additional 832 shares in the last quarter. Diversify Advisory Services LLC acquired a new stake in Gilead Sciences during the first quarter valued at approximately $316,000. Mission Wealth Management LP boosted its holdings in Gilead Sciences by 3.0% during the first quarter. Mission Wealth Management LP now owns 12,454 shares of the biopharmaceutical company’s stock worth $912,000 after buying an additional 368 shares in the last quarter. Finally, Prosperity Consulting Group LLC increased its holdings in shares of Gilead Sciences by 1,175.8% in the first quarter. Prosperity Consulting Group LLC now owns 52,985 shares of the biopharmaceutical company’s stock valued at $3,881,000 after buying an additional 48,832 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 5,490 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 36,847 shares of company stock worth $3,033,340 in the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

GILD traded up $0.46 during trading on Thursday, hitting $88.75. The stock had a trading volume of 887,176 shares, compared to its average volume of 7,001,724. The firm has a market cap of $110.57 billion, a PE ratio of 245.25, a P/E/G ratio of 3.07 and a beta of 0.18. The company has a 50 day simple moving average of $83.28 and a 200-day simple moving average of $73.86. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $89.74. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. The firm had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. Analysts expect that Gilead Sciences, Inc. will post 3.76 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research note on Wednesday, September 11th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research note on Monday, September 16th. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Finally, Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Ten research analysts have rated the stock with a hold rating, eleven have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.